[NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Dendritic cells (DC) were initially described as antigen presenting cells able to prime naive T cells. In fact, dendritic cells are also able to activate natural killer (NK) cells. The crosstalk between DC and NK is now regarded as a main stage in the initiation of innate and adaptative immune responses. Moreover, DC mediated-NK cell activation is particularly efficient since DC promote both effector functions and survival or proliferation of NK cells. Furthermore, recent publications in the field of NK cell biology underscore a role for NK cells in anti-tumor effects. NK cell-based immunotherapy should be reconsidered Here, we will report how pioneering immunotherapy trials based on natural cytotoxicity and progress in NK cell biology can promote NK cells in anti-tumor immune responses. Then, we will discuss the biological features of the DC/NK crosstalk and its implementations in immunotherapy protocols.
Borg
Christophe
C
Unité Inserm ERIT-M 0208, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France.
Taieb
Julien
J
Terme
Magali
M
Maruyama
Kuji
K
Flament
Caroline
C
Angevin
Eric
E
Zitvogel
Laurence
L
D002450:Cell Communication; D003713:Dendritic Cells / Q000276:immunology*; D020544:Graft vs Leukemia Effect / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000379:methods*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000502:physiology; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011971:Receptors, Immunologic / Q000276:immunology; D055607:Receptors, Natural Killer Cell; D014184:Transplantation, Homologous
D011971:Receptors, Immunologic; D055607:Receptors, Natural Killer Cell